AAPG
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on oncology, with lead programs Olverembatinib, a third-generation tyrosine kinase inhibitor approved in China for chronic myeloid leukemia with T315I mutations and resistant or intolerant disease, and Lisaftoclax, a Bcl-2 inhibitor approved in China for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma in patients previously treated with BTK inhibitors. The company is advancing registrational Phase 3 trials of Olverembatinib for additional CML indications and Philadelphia chromosome-positive acute lymphocytic leukemia, evaluating Lisaftoclax in combination with BTK inhibitors and azacitidine for CLL/SLL and acute myeloid leukemia or higher-risk myel